Current diagnostic antimicrobial susceptibility testing relies on the planktonic growth of isolates in nutrient rich, aerobic conditions. Here, we employ an alternative artificial sputum medium to study antimicrobial susceptibility of Pseudomonas aeruginosa biofilms under both aerobic and microaerophilic conditions more representative of the cystic fibrosis lung.
There is growing concern about the relevance of in vitro antimicrobial susceptibility tests when applied to isolates of P. aeruginosa from cystic fibrosis (CF) patients. Existing methods rely on single or a few isolates grown aerobically and planktonically. Predetermined cut-offs are used to define whether the bacteria are sensitive or resistant to any given antibiotic1. However, during chronic lung infections in CF, P. aeruginosa populations exist in biofilms and there is evidence that the environment is largely microaerophilic2. The stark difference in conditions between bacteria in the lung and those during diagnostic testing has called into question the reliability and even relevance of these tests3.
Artificial sputum medium (ASM) is a culture medium containing the components of CF patient sputum, including amino acids, mucin and free DNA. P. aeruginosa growth in ASM mimics growth during CF infections, with the formation of self-aggregating biofilm structures and population divergence4,5,6. The aim of this study was to develop a microtitre-plate assay to study antimicrobial susceptibility of P. aeruginosa based on growth in ASM, which is applicable to both microaerophilic and aerobic conditions.
An ASM assay was developed in a microtitre plate format. P. aeruginosa biofilms were allowed to develop for 3 days prior to incubation with antimicrobial agents at different concentrations for 24 hours. After biofilm disruption, cell viability was measured by staining with resazurin. This assay was used to ascertain the sessile cell minimum inhibitory concentration (SMIC) of tobramycin for 15 different P. aeruginosa isolates under aerobic and microaerophilic conditions and SMIC values were compared to those obtained with standard broth growth. Whilst there was some evidence for increased MIC values for isolates grown in ASM when compared to their planktonic counterparts, the biggest differences were found with bacteria tested in microaerophilic conditions, which showed a much increased resistance up to a >128 fold, towards tobramycin in the ASM system when compared to assays carried out in aerobic conditions.
The lack of association between current susceptibility testing methods and clinical outcome has questioned the validity of current methods3. Several in vitro models have been used previously to study P. aeruginosa biofilms7, 8. However, these methods rely on surface attached biofilms, whereas the ASM biofilms resemble those observed in the CF lung9 . In addition, reduced oxygen concentration in the mucus has been shown to alter the behavior of P. aeruginosa2 and affect antibiotic susceptibility10. Therefore using ASM under microaerophilic conditions may provide a more realistic environment in which to study antimicrobial susceptibility.
1. Preparation of Artificial Sputum Medium (ASM)
2. Determination of the Planktonic Sessile Cell Minimum Metabolic Inhibitory Concentration (PSMIC)
3. Determination of Biofilm Sessile Cell Minimum Inhibitory Concentration (BSMIC)
4. Representative Results
ASM biofilm formation is possible in small (2 ml) volumes and the biofilms are fully formed within 3 days (Figure 1A). This can be demonstrated by rigorously pipetting the biofilm, which should be difficult to disrupt. The microcolonies are comparable to those grown in larger volumes4 (Figure 1B). Figure 2 shows major differences between cells grown planktonically and in a biofilm as detected by electron microscopic image analysis. Biofilm cultures clearly show considerable levels of extracellular matrix surrounding the cells and individual structures within the biofilm are difficult to identify.
Several studies suggest that the biofilm lifestyle can affect antimicrobial susceptibility13, 14. Our small scale ASM assay can be used to determine the BSMIC of multiple antibiotics for multiple isolates at the same time. The workflow of the assay is shown in Figure 3. The effect of antibiotics on bacterial cell viability can be measured using the resazurin assay. Antibiotics, in this case tobramycin, can be added to the established biofilm and incubated for 24 h. After this the biofilm is disrupted and resazurin is added.
Metabolically active cells can reduce the resazurin dye resulting in a colour change from blue (resazurin) to pink (resorufin) 15. Figure 4A shows an example assay in which P. aeruginosa was incubated with different concentrations of tobramycin before biofilm disruption and addition of resazurin in a microtitre plate. The blue non-fluorescent colour indicates non-viable cells, whereas viable cells reduce the dye to the pink fluorescent form, resorufin. The SMIC can then be calculated by converting fluorescence into percentage remaining bacterial viability. Figure 4B shows the change in % viability with increasing tobramycin concentration. 10% viability was chosen as a cut-off in order to calculate the SMIC90.
Under aerobic conditions, the tobramycin SMIC90 values are higher for cells grown as a biofilm than those of planktonic cultures. Table 1 shows the variation in PSMIC90 and BSMIC90 for all isolates tested. Table 2 shows that under aerobic conditions, a dramatic increase in resistance to tobramycin (2 to >32 fold increase in SMIC) was observed for most isolates when grown in ASM (biofilm mode) compared to LB (planktonic mode). In addition, biofilms grown under microaerophilic conditions exhibited an increased SMIC of between 2 and >128-fold when compared to biofilms grown under aerobic conditions.
Figure 1. Biofilm formation of P. aeruginosa in ASM P. aeruginosa strain PAO1 forms macroscopically visible clumps (microcolonies) when grown in ASM. A, Biofilm formation in 30 ml ASM cultures (large-scale) after 7 days growth in screw cap glass Duran flasks . B, Biofilm formation in 2 ml ASM cultures (small-scale) after 3 days growth in 24-well polystyrene plates.
Figure 2. TEM micrographs of ASM biofilms A/C TEM micrograph (x;27,000) of PAO1 grown planktonically and in ASM, respectively, B/D TEM micrograph (x57,000) of PAO1grown planktonic and in ASM, respectively. Planktonically grown bacteria were cultivated overnight in LB broth. Biofilms were cultivated for 7 days in 30 ml ASM cultures. Black arrows refer to cells within the biofilm and stars refer to extracellular spaces. Scale bars = 1 μm.
Figure 3. Workflow of the ASM biofilm antimicrobial susceptibility assay.
Figure 4. Use of resazurin for the determination of antibiotic susceptibilities Bacterial cells were incubated with different concentrations of the antibiotic and the remaining metabolic activity was determined using resazurin. A, The blue non-fluorescent oxidized form of resazurin indicates non-viable cells and is reduced by metabolic active cells to pink fluorescent resorufin. B, Fluorescence intensity is converted into percentage of remaining bacterial viability. 10% viability was chosen as cut-off in order to calculate the MSMIC90. Click here to view larger figure.
Strains | PSMIC 90 (μg/ml) 1 | BSMIC 90 (μg/ml) 1 | ||
Aerobic | Microaerophilic2 | Aerobic | Microaerophilic 2 | |
PAO1 | 4 | 4 | 8 | >512 |
Liverpool Epidemic Strain (LES) isolates | ||||
LESB5821 | 8 | 64 | 64 | 128 |
LES40022 | 32 | 128 | 8 | 256 |
LESB25 | 16 | 32 | 256 | 512 |
LESB55 | 16 | 64 | 64 | >512 |
LESB64 | 16 | 64 | >512 | >512 |
LES43122 | 4 | 8 | 32 | >512 |
LESB49 | 16 | 64 | 64 | 256 |
LES109 | 32 | 128 | 32 | >512 |
Non-LES isolates | ||||
49461 | 16 | 32 | 16 | >512 |
59032 | 0.5 | 2 | 4 | >512 |
59073 | >512 | >512 | >512 | >512 |
59076 | 16 | 32 | 32 | >512 |
27 | 8 | 16 | 4 | >512 |
45 | 16 | 32 | 4 | >512 |
Table 1. Susceptibility of P. aeruginosa to tobramycin.
1For determination of PSMICs and BSMICs tobramycin was used in 2-fold serial dilutions
ranging from 512 – 0.5 μg/ml (n = 8 for each concentration) and 512 – 1 μg/ml (n = 4 for each
concentration), respectively;; PSMICs were determined using the standard
microdilution method1.
2Microaerophilic conditions were 5 % O2, 10 % CO2, and 85 % N2.
Strain | PSMIC90/BSMIC90fold change1 | |||
PSMICaerobic → PSMICmicroaerophilic |
BSMICaerobic → BSMICmicroaerophilic |
PSMICaerobic → BSMICaerobic |
PSMICmicroaerophilic → BSMICmicroaerophilic |
|
PAO1 | 0 | >64 | 2 | 128 |
LES isolates | ||||
LESB58 | 8 | 2 | 8 | 2 |
LES400 | 4 | 32 | 0.25 | 2 |
LESB25 | 2 | 2 | 16 | 16 |
LESB55 | 4 | >8 | 4 | >8 |
LESB64 | 4 | ND | >32 | >8 |
LES431 | 2 | >16 | 8 | >64 |
LESB49 | 4 | 4 | 4 | 4 |
LES109 | 4 | 16 | 0 | >4 |
Non-LES isolates | ||||
49461 | 2 | >32 | 0 | >16 |
59032 | 4 | >128 | 8 | >256 |
59073 | ND | ND | ND | ND |
59076 | 2 | >16 | 2 | >16 |
27 | 2 | >128 | 0.5 | >32 |
45 | 2 | >128 | 0.25 | >16 |
Table 2. Fold change of PSMICs and BSMICs to tobramycin.
1ND, not determined; values in bold indicate SMIC fold changes >10.
In this study we used a novel in vitro model based on ASM to replicate P. aeruginosa biofilm conditions within the CF lung4. The model was modified successfully for small-scale, high-throughput testing of antimicrobial agents.
The critical steps of this assay are:
An obvious application of the small-scale ASM biofilm model is the more realistic determination of biofilm antimicrobial susceptibilities (BSMIC90). Anaerobic and microaerophilic niches are present in the CF lung and there is evidence that oxygen is limited deep within mature biofilms2, 17. Here we demonstrate that 10/14 clinical P. aeruginosa isolates from CF patient sputa exhibit a considerable (4 – ≥ 128 fold) decrease in sensitivity to tobramycin under microaerophilic conditions in ASM. The results of this study suggest that antibiotics, such as tobramycin, might be less effective against P. aeruginosa infections in the CF lung than indicated by conventional susceptibility testing methods. These results reflect previous studies on the antimicrobial susceptibility of biofilms 10. Small-scale ASM assays thus provide a simple high throughput platform for generating meaningful antibiotic susceptibility data to better inform therapeutic decisions. The assay is limited in the same way as conventional antibiotic susceptibility testing in that single colonies are picked for screening that may not be representative of the whole population. However, we believe that an approach (i) using non-surface attached biofilm growth and (ii) applicable to microaerophilic conditions, represents a clear alternative and a potential improvement to existing methods. We conclude that this assay is an appropriate model to study P. aeruginosa biofilm populations. Further testing in clinical settings would ascertain whether antibiotic susceptibilities based on biofilm-grown P. aeruginosa could lead to different antibiotic choices with potentially improved microbiological and clinical outcomes. Similar investigations using classic biofilm models have shown that BSMIC values lead to different recommendations for antibiotic treatment5,17.
In addition to testing for the effectiveness of anti-infective agents, the ASM system represents a cheap, simple and reproducible alternative to animal models for studies such as those aimed at understanding the diversification of P. aeruginosa populations. We have observed extensive heterogeneity in natural populations of P. aeruginosa recovered from CF patient sputa 18, 19. Similar phenotypic and genotypic diversification can be observed during growth in ASM4 (and our unpublished data), making it an attractive in vitro model of the CF lung conditions. The relative simplicity of the ASM model makes it easy to design long-term adaptation experiments aimed, for example, at monitoring the effects of antibiotics or other stresses on P. aeruginosa population divergence. In addition, other bacterial pathogens can be grown in ASM. For example, Fouhy et al. 2007 have used ASM to study biofilm formation by S. maltophillia20.
The authors have nothing to disclose.
We acknowledge the support of the United Kingdom National Institute for Health Research, the Dr Hadwen Trust for Humane Research, the UK’s leading medical research charity funding exclusively non-animal research techniques to replace animal experiments, and the Wellcome Trust (Grant 089215). We also acknowledge Novartis Pharmaceuticals UK Ltd (unrestricted educational grant).
Name of reagent | Company | Catalogue number |
DNA from fish sperm | Sigma-Aldrich | 74782 |
Mucin from porcine stomach, type II | Sigma-Aldrich | M2378 |
L-Alanine | Acros Organics | 102830250 |
L-Arginine | Sigma-Aldrich | A5006 |
L(+)-Asparagine monohydrate | Acros Organics | 175271000 |
L(+)-Aspartic acid | Acros Organics | 105041000 |
L-Cysteine | Sigma-Adrich | 168149 |
L(+)-Glutamic acid | Acros Organics | 156211000 |
L-Glutamine | Sigma-Aldrich | G3126 |
Glycine | Acros Organics | 220911000 |
L-Histidine | Sigma-Adrich | H8000 |
L-Isoleucine | Sigma-Aldrich | I2752 |
L-Leucine | Sigma-Aldrich | L8000 |
L(+)-Lysine monohydrochloride | Acros Organics | 125222500 |
L-Methionine | Sigma-Aldrich | M9625 |
L-Phenylalanine | Acros Organics | 130310250 |
L-Proline | Sigma-Aldrich | P0380 |
L-Serine | Acros Organics | 132660250 |
L-Threonine | Acros Organics | 138930250 |
L(-)-Tryptophan | Acros Organics | 140590250 |
L-Tyrosine | Acros Organics | 140641000 |
L-Valine | Sigma-Aldrich | V0500 |
Diethylenetriaminepentaacetic acid | Sigma-Aldrich | 32318 |
NaCl | Fisher Scientific | S/3160/60 |
KCl | BDH | BDH0258 |
KOH | BDH | BDH0262 |
Egg yolk emulsion | Sigma-Aldrich | 17148 |
ME 2 diaphragm vacuum pump | Vacuubrand | 696126 |
Steritop filters (Pore size: 0.22 μm, Neck size: 45 mm) | Millipore | SCGPT10RE |
Luria-Bertani medium | Sigma | L2897 |
96-well microtitre plates | Sarstedt | 82.1581 |
24-well tissue culture-treated plates | Iwaki | 3820-024 |
CampyGen gas generation packs | Oxoid | CN0025 |
Microaerophilic chamber | Oxoid | HP0011 |
Tobramycin sulphate | Sigma-Aldrich | T1783 |
Cellulase, from Aspergillus niger | Sigma-Aldrich | 22178 |
Resazurin | Sigma-Aldrich | 199303 |
Citrate.H20 | BDH | BDH0288 |
Fluostar omega microplate reader | BMG-Labtech | SPECTROstar Omega |